Mehran Yusuf is an Oncology physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 76 publications with 843 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
2 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
35.5%Opioid Agonist35.5%Oxycodone Hcl100%Part D≥27 patientsSensory organs
29.8%Corticosteroid29.8%Betamethasone Valerate50%Dexamethasone50%Part D≥16 patientsCardiovascular
14%Antiarrhythmic14%Lidocaine Hcl Viscous100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- In‐Silico Trial of Same‐Day Simulation‐Free Spatially Fractionated Adaptive Radiotherapy (SF 2 ‐ART)
Journal of Applied Clinical Medical Physics
2026 - Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2025 - Clinical practice guidelines for the management of basal cell carcinoma in Gorlin syndrome
Journal of the American Academy of Dermatology
2025 - NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Suzanne Oparil, MD
University of Alabama at Birmingham
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Bruce Korf, MD
University of Alabama at Birmingham
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”